Drugs and Biologicals With Average Annual Total Cost Under Part D Below the Applicable Threshold Under section 1860D-14B(g)(1)(B) of the Act, a drug or biological is excluded from the definition of a Part D rebatable drug if the average annual total cost under Part D for such period per individual who uses such a drug or biological product is less than $100 per year, as determined by the Secretary using the most recent data available, or, if data are not available, as estimated by the Secretary
Santucci C, Bosetti C, Peveri G, et al (2019) Doserisk relationships between cigarette smoking and ovarian cancer histotypes: a comprehensive meta-analysis
Int J Health Geogr 24 , 32 (2025)
Based on our analyses utilizing data from the CY 2022 performance period/2024 MIPS payment year, this proposed methodology would increase the mean cost performance category score (unweighted) for clinicians with a cost performance category score from 59 out of 100 to 71 out of 100 (an increase of 11.9 points)
Britton suggested that the real value of the deal lay in continuing the "subliminal" links between the two brands
.png)
